Appeals system and its outcomes in National Health Insurance in Taiwan

Annals of Pharmacotherapy

Volumn 40, Issue 3, 2006, Pages 506-511

  Lin, Swu Jane ^a   Kuo, Shih Chen ^b   Yang, Yea Huei Kao ^c,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; Appeals system; National Health Insurance; Prior authorization; Taiwan

Indexed keywords

DONEPEZIL; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; BILLING AND CLAIMS; COST CONTROL; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DRUG COST; DRUG USE; HEALTH CARE; HEALTH CARE FINANCING; HEALTH CARE UTILIZATION; HUMAN; MULTIVARIATE ANALYSIS; NATIONAL HEALTH INSURANCE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEGOTIATING; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; TAIWAN;

EID: 33645092641     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G437     Document Type: Article

References (30)

1. Yang Kao YH, Lee HL, Jia SW. Analysis of drug utilization and expenditure of National Health Insurance reimbursement by anatomical therapeutic chemical classification. Final report. Taipei: Department of Health, Bureau of National Health Insurance, 2001.
2. The National Health Insurance statistics. Department of Health, Bureau of National Health Insurance. www.nhi.gov.tw/webdata/AttachFiles/Attach_1_s2003. pdf (accessed 2006 Feb 18).
3. Chiu H, Hu F. [Introduction of pharmacoeconomics (II)-pharmacoeconomics of cholesterase inhibitors in Alzheimer's disease] Chinese. Formosan J Med 2003;7:277-83.
4. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-6.
5. Kawas CH. Clinical practice. Early Alzheimer's disease. N Engl J Med 2003;349:1056-63.
6. Knopman D. Pharmacotherapy for Alzheimer's disease: 2002. Clin Neuropharmacol 2003;26:93-101.
7. Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physician deception of third-party payers. Arch Intern Med 1999;159:2263-70.
8. Wynia MK, Cummins DS, VanGeest JB, Wilson IB. Physician manipulation of reimbursement rules for patients: between a rock and a hard place. JAMA 2000;283:1858-65.
9. Werner RM, Alexander GC, Fagerlin A, Ubel PA. The "Hassle Factor": what motivates physicians to manipulate reimbursement rules? Arch Intern Med 2002;162:1134-9.
10. Webb S, Lloyd M. Prescribing and referral in general practice: a study of patients' expectations and doctors' actions. Br J Gen Pract 1994;44:165-9.
11. Karras DJ, Ong S, Moran GJ, et al. Antibiotic use for emergency department patients with acute diarrhea: prescribing practices, patient expectations, and patient satisfaction. Ann Emerg Med 2003;42:835-42.
12. Britten N, Ukoumunne O. The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to prescribe: a questionnaire survey. BMJ 1997;315:1506-10.
13. Macfarlane J, Holmes W, Macfarlane R, Britten N. Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. BMJ 1997;315:1211-4.
14. Wilson IB, Dukes K, Greenfield S, Kaplan S, Hillman B. Patients' role in the use of radiology testing for common office practice complaints. Arch Intern Med 2001;161:256-63.
15. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-35.
16. Linder JA, Singer DE, Stafford RS. Association between antibiotic prescribing and visit duration in adults with upper respiratory tract infections. Clin Ther 2003;25:2419-30.
17. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med 1995;332:1612-7.
18. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9.
19. Momani AA, Madhavan SS, Nau DP. Impact of NSAIDs prior authorization policy on patients' QoL. Ann Pharmacother 2002;36:1686-91. DOI 10.1345/aph.1C008
20. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther 2004;26:1518-32.
21. Mental health: a report of the Surgeon General. 1999. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health. 1999.
22. President's Council on Bioethics. Beyond therapy: biotechnology and the pursuit of happiness. New York: Dana Press, 2003.
23. Anderson R, Smith B. Deaths: leading causes for 2002. National vital statistics reports. Vol. 53, no. 17. Hyattsville, MD: National Center for Health Statistics, 2005.
24. Conrad P, Shneider JW. Deviance and medicalization: from badness to sickness. Philadelphia: Temple University Press, 1980.
25. Conrad P. The shifting engines of medicalization. J Health Soc Behav 2005;46:3-14.
26. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
27. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004:CD001747.
28. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64.
29. Kmietowicz Z. NICE proposes to withdraw Alzheimer's drugs from NHS. BMJ 2005;330:495.
30. Bess DT, Blackford JN, Regan JJ, Alderson A. Mediating denials of pharmaceutical services: an alternative to traditional appeals. Am J Health Syst Pharm 2001;58:2147-50.